These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38882761)

  • 1. COVID-19 Booster Vaccination Adverse Effects and Willingness to Receive a Yearly Booster Dose among Members of Health Sciences Faculties: A Descriptive Cross-Sectional Study.
    Pandarathodiyil AK; Veerabhadrappa SK; Nabillah Ghani WM; Termizi Bin Zamzuri A
    J Pharm Bioallied Sci; 2024 Apr; 16(Suppl 2):S1776-S1783. PubMed ID: 38882761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Willingness to accept a second COVID-19 vaccination booster dose among healthcare workers in Italy.
    Della Polla G; Miraglia Del Giudice G; Folcarelli L; Napoli A; Angelillo IF;
    Front Public Health; 2022; 10():1051035. PubMed ID: 36568799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
    Makanut S; Wangteeraprasert A; Jitpewngam W; Ngoenkam J; Pongcharoen S
    Vaccine; 2023 Jun; 41(29):4335-4340. PubMed ID: 37301707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parents' willingness to vaccinate themselves and their children with the booster vaccine against SARS-CoV-2: A cross-sectional study in Puyang city, China.
    Zhou Y; Li GX; Zhao TS; Du J; Zhang WX; Xie MZ; Chen LY; Zeng J; Wang C; Liu B; Liu YQ; Cui F; Lu QB
    J Med Virol; 2023 Jan; 95(1):e28256. PubMed ID: 36305477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
    Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial.
    Sharifi Aliabadi L; Karami M; Barkhordar M; Hashemi Nazari SS; Kavousi A; Ahmadvand M; Vaezi M
    Front Immunol; 2023; 14():1237916. PubMed ID: 37593732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety Profile of Homologous and Heterologous Booster COVID-19 Vaccines in Physicians in Quito-Ecuador: A Cross-Sectional Study.
    Flores-Lastra N; Rivadeneira-Dueñas J; Fuenmayor-González L; Guayasamín-Tipanta G; Jácome-García M; Otzen T; Manterola C
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis.
    Deng J; Ma Y; Liu Q; Du M; Liu M; Liu J
    Int J Environ Res Public Health; 2022 Aug; 19(17):. PubMed ID: 36078466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland.
    Rzymski P; Poniedziałek B; Fal A
    Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-dimensional potential factors influencing COVID-19 vaccine booster acceptance and hesitancy among university academic community in Bangladesh: A cross-sectional comparative study.
    Roy DN; Azam MS; Islam E
    PLoS One; 2023; 18(4):e0281395. PubMed ID: 37053270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pattern of self-reported adverse events related to COVID-19 vaccines in Saudi Arabia: A nationwide study.
    Alkhalifah JM; Al Seraihi A; Al-Tawfiq JA; Alshehri BF; Alhaluli AH; Alsulais NM; Alessa MM; Seddiq W; Aljeri T; Qahtani MH; Barry M; Al-Otaiby M
    Front Public Health; 2023; 11():1043696. PubMed ID: 36908451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
    Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
    Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Willingness to receive a booster dose of inactivated coronavirus disease 2019 vaccine in Taizhou, China.
    Tung TH; Lin XQ; Chen Y; Zhang MX; Zhu JS
    Expert Rev Vaccines; 2022 Feb; 21(2):261-267. PubMed ID: 34894991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of the Third (Booster) Dose of COVID-19 Vaccine Intention among the Healthcare Workers in Saudi Arabia: An Online Cross-Sectional Survey.
    Alobaidi S; Hashim A
    Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Hardt K; Vandebosch A; Sadoff J; Le Gars M; Truyers C; Lowson D; Van Dromme I; Vingerhoets J; Kamphuis T; Scheper G; Ruiz-Guiñazú J; Faust SN; Spinner CD; Schuitemaker H; Van Hoof J; Douoguih M; Struyf F;
    Lancet Infect Dis; 2022 Dec; 22(12):1703-1715. PubMed ID: 36113538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of Willingness of the General Public to Receive a Second COVID-19 Booster Dose or a New COVID-19 Vaccine: A Cross-Sectional Study in Greece.
    Galanis P; Vraka I; Katsiroumpa A; Siskou O; Konstantakopoulou O; Katsoulas T; Mariolis-Sapsakos T; Kaitelidou D
    Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.